IntelliPharmaCeutics International (IntelliPharmaCeutics International) Operating Margin %

: -2,518.84% (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. IntelliPharmaCeutics International's Operating Income for the three months ended in Aug. 2023 was $-1.74 Mil. IntelliPharmaCeutics International's Revenue for the three months ended in Aug. 2023 was $0.07 Mil. Therefore, IntelliPharmaCeutics International's Operating Margin % for the quarter that ended in Aug. 2023 was -2,518.84%.

The historical rank and industry rank for IntelliPharmaCeutics International's Operating Margin % or its related term are showing as below:

IPCIF' s Operating Margin % Range Over the Past 10 Years
Min: -4311.24 Med: -333.66 Max: -40.28
Current: -279.12

IPCIF's Operating Margin % is ranked worse than
55.8% of 1025 companies
in the Biotechnology industry
Industry Median: -179.29 vs IPCIF: -279.12

IntelliPharmaCeutics International's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

IntelliPharmaCeutics International's Operating Income for the three months ended in Aug. 2023 was $-1.74 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Aug. 2023 was $-2.53 Mil.

IntelliPharmaCeutics International Operating Margin % Historical Data

The historical data trend for IntelliPharmaCeutics International's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Operating Margin %

-777.93

-225.08

-333.67

-4,319.70

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Operating Margin %																-1,926.32	-1,533.33	-92.33	-6.46	-2,518.84

Competitive Comparison

For the Biotechnology subindustry, IntelliPharmaCeutics International's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Operating Margin % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Operating Margin % falls into.

IntelliPharmaCeutics International Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

IntelliPharmaCeutics International's Operating Margin % for the fiscal year that ended in Nov. 2022 is calculated as

Operating Margin %	=	Operating Income (A: Nov. 2022 )	/	Revenue (A: Nov. 2022 )
	=	-2.851	/	0.066
	=	-4,319.70 %

IntelliPharmaCeutics International's Operating Margin % for the quarter that ended in Aug. 2023 is calculated as

Operating Margin %	=	Operating Income (Q: Aug. 2023 )	/	Revenue (Q: Aug. 2023 )
	=	-1.738	/	0.069
	=	-2,518.84 %

IntelliPharmaCeutics International (OTCPK:IPCIF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.

Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

IntelliPharmaCeutics International Operating Margin % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Operating Margin %

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.